The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, Myovant, oral, relugolix | 2 Comments »
Some time ago we noted that there were three oral (as opposed to injectable) LHRH antagonists in development for the treatment of prostate cancer, i.e., drugs like degarelix (Firmagon) that could be given by mouth as opposed to needing to be injected. … READ MORE …
Filed under: Drugs in development | Tagged: LHRH antagonist, oral, TAK-385 | 16 Comments »
At least three new LHRH receptor antagonists — i.e., drugs similar to degarelix (Firmagon) — are in development at the present time: elagolix, relugolix, and ASP-1707. However, unlike degarelix, all three are agents that would act as oral drugs as opposed to drugs one has to be given as long-term injections. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: antagonist, ASP-1707, elagolix, LHRH, oral, relugolix, TAK-385 | Leave a comment »
Volunteers are now receiving doses of GTx’s luteinizing hormone (LH) inhibitor — GTx-758 — in a Phase I clinical trial. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: androgen deprivation, GTx-758, oral, Phase I | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 